Publications

Detailed Information

Overexpression of p53, Mutation of hMLH1 and Microsatellite Instability in Gastric Carcinomas: Clinicopathologic Implications and Prognosis

DC Field Value Language
dc.contributor.authorKwon, Junsik-
dc.contributor.authorLee, Ju-Hee-
dc.contributor.authorJee, Ye Seob-
dc.contributor.authorPark, Do-Jung-
dc.contributor.authorLee, Hyuk-Joon-
dc.contributor.authorLee, Kuhn Uk-
dc.contributor.authorLee, Hye Seung-
dc.contributor.authorYang, Han-Kwang-
dc.contributor.authorKim, Hyung-Ho-
dc.date.accessioned2012-06-29T06:41:38Z-
dc.date.available2012-06-29T06:41:38Z-
dc.date.issued2010-08-
dc.identifier.citationJOURNAL OF THE KOREAN SURGICAL SOCIETY; Vol.79(2); 94-102ko_KR
dc.identifier.issn2233-7903-
dc.identifier.urihttps://hdl.handle.net/10371/77968-
dc.description.abstractPurpose: Mutated p53 is a tumor suppressor gene, hMLH1 is a mismatch repair gene, and hypermethylation of hMLH1 follows microsatellite instability (MSI). This research`s aim is to investigate mutated p53, inactivated hMLH1 and MSI in gastric cancer and their clinicopathologic implications. Methods: Between 2003 and 2007, 618 patients underwent curative radical gastrectomy for gastric cancer at Seoul National University Bundang Hospital in Korea. We reviewed their medical charts and the pathologic reports with immunohistochemistry for p53, hMLH1 and polymerase chain reaction for MSI in 509, 499, and 561 cases, respectively. These genetic markers were statistically compared with clinicopathologic features and postoperative survival. Results: The expression ratios of mutated p53, inactivated hMLH1, and MSI were 32.8%, 8.4%, and 8.7%, respectively. Mutation of p53 occurred more frequently in aged group (over 40), differentiated group (against the non-differentiated group), intestinal type, infiltrative type and positive lymph node metastasis group. Inactivated hMLH1 occurred more frequently in aged group, differentiated group, intestinal type and expanding growth type group. MSI was found more frequently in aged group, intestinal type and expanding growth type group. All three genetic markers had no significant associations with the 5-year survival. Conclusion: We identified significant relationships between mutated p53, inactivated hMLH1, and MSI with some clinicopathologic features of gastric cancer. However, there were no apparent relationships between p53, hMLH1, and MSI and prognosis.ko_KR
dc.language.isoenko_KR
dc.publisherKOREAN SURGICAL SOCIETYko_KR
dc.subjectGastric cancerko_KR
dc.subjectp53ko_KR
dc.subjectCarcinogenesisko_KR
dc.subjectMicrosatellite instabilityko_KR
dc.subjecthMLH1ko_KR
dc.titleOverexpression of p53, Mutation of hMLH1 and Microsatellite Instability in Gastric Carcinomas: Clinicopathologic Implications and Prognosisko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor권준식-
dc.contributor.AlternativeAuthor이주희-
dc.contributor.AlternativeAuthor지예섭-
dc.contributor.AlternativeAuthor박도정-
dc.contributor.AlternativeAuthor김형호-
dc.contributor.AlternativeAuthor이혁준-
dc.contributor.AlternativeAuthor양한광-
dc.contributor.AlternativeAuthor이건욱-
dc.contributor.AlternativeAuthor이혜승-
dc.identifier.doi10.4174/jkss.2010.79.2.94-
dc.citation.journaltitleJOURNAL OF THE KOREAN SURGICAL SOCIETY-
dc.description.citedreferenceKU KB, 2007, J KOREAN SURG SOC, V72, P283-
dc.description.citedreferenceWOERNER SM, 2006, CANCER BIOMARK, V2, P69-
dc.description.citedreferenceLIU P, 2005, WORLD J GASTROENTERO, V11, P4904-
dc.description.citedreferenceLee HS, 2002, MODERN PATHOL, V15, P632-
dc.description.citedreferenceNakajima T, 2001, INT J CANCER, V94, P208-
dc.description.citedreferenceSamowitz WS, 2001, AM J PATHOL, V158, P1517-
dc.description.citedreferenceRugge M, 2000, J CLIN PATHOL-MOL PA, V53, P207-
dc.description.citedreferenceWu MS, 2000, GENE CHROMOSOME CANC, V27, P403-
dc.description.citedreferenceOH SH, 2000, J KOREAN SURG SOC, V59, P206-
dc.description.citedreferenceFleisher AS, 1999, CANCER RES, V59, P1090-
dc.description.citedreferenceLeung SY, 1999, CANCER RES, V59, P159-
dc.description.citedreferenceMonig SP, 1997, DIGEST DIS SCI, V42, P2463-
dc.description.citedreferenceThibodeau SN, 1996, CANCER RES, V56, P4836-
dc.description.citedreferenceStarzynska T, 1996, CANCER, V77, P2005-
dc.description.citedreferenceDosSantos NR, 1996, GASTROENTEROLOGY, V110, P38-
dc.description.citedreferencePeddanna N, 1995, ANTICANCER RES, V15, P2055-
dc.description.citedreferenceTAMURA G, 1995, CANCER RES, V55, P1933-
dc.description.citedreferenceSERUCA R, 1995, INT J CANCER, V64, P32-
dc.description.citedreferenceCORREA P, 1994, CANCER RES, V54, pS1941-
dc.description.citedreferenceBODMER W, 1994, NAT GENET, V6, P217-
dc.description.citedreferenceRHYU MG, 1994, ONCOGENE, V9, P29-
dc.description.citedreferenceUCHINO S, 1993, INT J CANCER, V54, P759-
dc.description.citedreferenceTAHARA E, 1993, J CANCER RES CLIN, V119, P265-
dc.description.citedreferenceCORREA P, 1992, CANCER RES, V52, P6735-
dc.description.citedreferenceMARTIN HM, 1992, INT J CANCER, V50, P859-
dc.description.citedreferenceHOLLSTEIN MC, 1991, CANCER RES, V51, P4102-
dc.description.citedreferenceYONISHROUACH E, 1991, NATURE, V352, P345-
dc.description.citedreferenceHARRIS AL, 1990, J PATHOL, V162, P5-
dc.description.tc0-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share